Evidence map›Paper›PMID 41975814›Full record

ReviewDiagnostics (Basel, Switzerland)2026

Artificial Intelligence in Ocular Surface Tumors: Current Advances, Challenges, and Future Directions.

Hamidreza Ghanbari, Nikoo Bayan, Shakiba Rahimi, Farhad Salari, Mohammadreza Toghyani DolatAbadi, Mohammad Soleimani

Abstract readReview
In one paragraph

Review in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hamidreza GhanbariEye Research Center, Farabi Eye Hospital, Tehran 1336616351, Iran.ORCID 0009-0003-1480-8393
Nikoo BayanSchool of Medicine, Tehran University of Medical Sciences, Tehran 1416753955, Iran.ORCID 0000-0001-7264-0953
Shakiba RahimiSchool of Medicine, Tehran University of Medical Sciences, Tehran 1416753955, Iran.
Farhad SalariEye Research Center, Farabi Eye Hospital, Tehran 1336616351, Iran.
Mohammadreza Toghyani DolatAbadiSchool of Medicine, Shahid Beheshti University of Medical Sciences, Tehran 1983535511, Iran.
Mohammad SoleimaniDepartment of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-6546-3546

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ocular surface tumors (OSTs) are rare but potentially life-threatening neoplasms encompassing entities such as ocular surface squamous neoplasia (OSSN), conjunctival melanoma, and lymphoma. Accurate diagnosis often requires expert ophthalmologists and pathologists, compounded by the reliance on advanced imaging modalities, with excisional biopsy being the gold standard. These limitations underscore the need for less invasive, accessible diagnostic approaches, where artificial intelligence (AI) holds significant promise. This review provides a comprehensive overview of AI advancements in OST management. It begins with definitions of AI and its key branches, followed by an examination of AI models applied to ophthalmic tumors using imaging data. Current developments in AI-related diagnostic tools for OSTs are discussed, highlighting their potential to enhance patient management, with classifications based on imaging modalities and specific OST types. Finally, the review addresses main challenges in AI implementation, including data limitations and ethical considerations, while outlining future directions to integrate AI into clinical ophthalmology practice. By bridging technological innovation with clinical needs, AI shows promise in OST diagnosis and management, ultimately improving outcomes in this challenging condition.

Indexed as

artificial intelligenceconjunctival lymphomaconjunctival melanomaocular surface squamous neoplasiaocular surface tumors

Identifiers

PMID41975814
PMCPMC13072765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.